Bryan E. Jones

Bryan E. Jones

Auto-generated profile, based on publicly available information

Bryan E. Jones

Department of Chemistry, Pennsylvania State University, University Park 16802

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Cell Reports
Verified
Journal Article
Open access
KWKathryn Westendorf
Kathryn Westendorf
SŽStefanie Žentelis
Stefanie Žentelis
LWLingshu Wang
Lingshu Wang
DFDenisa Foster
Denisa Foster
PVPeter Vaillancourt
Peter Vaillancourt
BBBryan C. Barnhart
Bryan C. Barnhart
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.

12 May 2021 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
BJBryan E. Jones
Bryan E. Jones
PBPatricia Brown-Augsburger
Patricia Brown-Augsburger
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
KWKathryn Westendorf
Kathryn Westendorf
JDJulian Davies
Julian Davies
EFEster Falconer
Ester Falconer
LY-CoV555, a SARS-CoV-2 spike protein–specific antibody, neutralizes SARS-CoV-2 and protects the airways of nonhuman primates against infection.

3 October 1995 in Biochemistry
Verified
Journal Article
Closed access
JZJill A. Zitzewitz
Jill A. Zitzewitz
OBOsman Bilsel
Osman Bilsel
JLJiabin Luo
Jiabin Luo
BJBryan E. Jones
Bryan E. Jones
CMC. Robert Matthews
C. Robert Matthews

1 October 1997 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BJBryan E. Jones
Bryan E. Jones
VDValèrie Dossonnet
Valèrie Dossonnet
EKElke Küster
Elke Küster
WHWolfgang Hillen
Wolfgang Hillen
JDJosef Deutscher
Josef Deutscher
RKRachel E. Klevit
Rachel E. Klevit
Catabolite repression of a number of catabolic operons in bacilli is mediated by the catabolite control protein CcpA, the phosphocarrier protein HPr from the phosphoenolpyruvate-dependent sugar transport system (PTS), and a cis-acting DNA sequence termed the catabolite-responsive element (cre). We present evidence that CcpA interacts with HPr that is phosphorylated at Ser46 (Ser(P) HPr) and that these proteins form a specific ternary complex with cre DNA. Titration experiments following the circular dichroism signal of the cre DNA indicate that this complex consists of two molecules of Ser(P) HPr, a CcpA dimer, and the cre sequence. Limited proteolysis experiments indicate that the domain structure of CcpA is similar to other members of the LacI/GalR family of helix-turn-helix proteins, comprised of a helix-turn-helix DNA domain and a C-terminal effector domain. NMR titration of Ser(P) HPr demonstrates that the isolated C-terminal domain of CcpA forms a specific complex with Ser(P) HPr but not with unphosphorylated HPr. Based upon perturbations to the NMR spectrum, we propose that the binding site of the C-terminal domain of CcpA on Ser(P) HPr forms a contiguous surface that encompasses both Ser(P)46 and His15, the site of phosphorylation by enzyme I of the PTS. This allows CcpA to recognize the phosphorylation state of HPr, effectively linking the process of sugar import via the PTS to catabolite repression in bacilli.

1 March 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
ASAsif A. Sharfuddin
Asif A. Sharfuddin
RSRuben M. Sandoval
Ruben M. Sandoval
DBDavid T. Berg
David T. Berg
GMGrant E. McDougal
Grant E. McDougal
SCSilvia B. Campos
Silvia B. Campos
BMBruce A. Molitoris
Bruce A. Molitoris
Altered coagulation and inflammation contribute to the pathogenesis of ischemic renal injury. Thrombomodulin is a necessary factor in the anticoagulant protein C pathway and has inherent anti-inflammatory properties. We studied the effect of soluble thrombomodulin (sTM) in a hypoperfusion model of ischemic kidney injury. To markedly reduce infrarenal aortic blood flow and femoral arterial pressures, we clamped the suprarenal aorta of rats, occluding them 90%, for 60 min. Reversible acute kidney injury (AKI) occurred at 24 h in rats subjected to hypoperfusion. Histologic analysis at 24 h revealed acute tubular necrosis (ATN), and intravital two-photon microscopy showed flow abnormalities in the microvasculature and defects of endothelial permeability. Pretreatment with rat sTM markedly reduced both I-R-induced renal dysfunction and tubular histologic injury scores. sTM also significantly improved microvascular erythrocyte flow rates, reduced microvascular endothelial leukocyte rolling and attachment, and minimized endothelial permeability to infused fluorescence dextrans, assessed by intravital quantitative multiphoton microscopy. Furthermore, sTM administered 2 h after reperfusion protected against ischemia-induced renal dysfunction at 24 h and improved survival. By using an sTM variant, we also determined that the protective effects of sTM were independent of its ability to generate activated protein C. These data suggest that sTM may have therapeutic potential for ischemic AKI.

1 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
BJBryan E. Jones
Bryan E. Jones
PBPatricia L. Brown-Augsburger
Patricia L. Brown-Augsburger
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
KWKathryn Westerndorf
Kathryn Westerndorf
JDJulian Davies
Julian Davies
EFEster Falconer
Ester Falconer
SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection. One Sentence Summary: LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.